Compare ACADIA Pharmaceuticals Inc. (ACAD) vs United States Copper Index Fund (CPER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs United States Copper Index Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while United States Copper Index Fund trades at $40.22. Which is the better fit depends on your goals.
| ACAD | CPER | |
|---|---|---|
Market Cap | $5.06B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $29.41 | $40.85 |
52-Week Low | $20.06 | $27.57 |
Enterprise Value | $4.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
CPER, the United States Copper Index Fund, trades at $39.9, down 2.11% today, amid a broader bullish technical signal driven by moving averages. Recent news highlights record copper prices fueled by supply disruptions and strong demand from electrification and AI infrastructure. Key support sits at $39, with resistance at $41. Financial ratios are not applicable as this is an ETF tracking copper futures.
The outlook for CPER is positive, supported by structural copper demand trends, but carries risks from potential supply normalization and commodity price volatility. Investors gain exposure to copper's price movements without direct company fundamentals, making it a pure play on industrial metal trends influenced by global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
